Pembrolizumab receives FDA approval for people with early-stage, triple-negative breast cancer
Full article:

The FDA approved the immunotherapy drug pembrolizumab (Keytruda) for the treatment of early-stage triple-negative breast cancer that has a high risk for recurrence.  This marks the first approval for this type of drug, known as an immune checkpoint inhibitor, for the treatment of early-stage breast cancer. (posted 9/2/21)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies enrolling people with early-stage, TNBC.  

A number of other clinical trials for patients with early-stage TNBC can be found here.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.